ArticleRSC advances2019
A Maitake (
Article in RSC advances, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 44 citations in OpenAlex.
- Medicinal Mushrooms and Their Bioactive Compounds: From Traditional Use to Therapeutic Potential.Molecules (Basel, Switzerland) · 2026Review
- Emerging neuroprotective mechanisms and therapeutic potential of natural polysaccharides in Alzheimer's disease.Frontiers in aging neuroscience · 2026Review
- Article
- Natural Neuroinflammatory Modulators: Therapeutic Potential of Fungi-Derived Compounds in Selected Neurodegenerative Diseases.Molecules (Basel, Switzerland) · 2025Review
- Macroalgae Polysaccharides Enhance Brain Health by Mitigating Scopolamine-induced Oxidative Stress and Inflammation Via Nrf-2/TLR4/NF-kB Pathways.Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology · 2025Article
- Dietary Supplementation of Edible MushroomNutrients · 2025Article
- Article
- Review
- Macrofungi as Medicinal Resources in Uzbekistan: Biodiversity, Ethnomycology, and Ethnomedicinal Practices.Journal of fungi (Basel, Switzerland) · 2023Review
- Unveiling the Therapeutic Potentials of Mushroom Bioactive Compounds in Alzheimer's Disease.Foods (Basel, Switzerland) · 2023Review
- Characterization and in-vitro Alzheimer's properties of exopolysaccharide from Bacillus maritimus MSM1.Scientific reports · 2023Article
- Multiple Metabolites Derived from Mushrooms and Their Beneficial Effect on Alzheimer's Diseases.Nutrients · 2023Review
- β-Glucan attenuates cognitive impairment of APP/PS1 mice via regulating intestinal flora and its metabolites.CNS neuroscience & therapeutics · 2023Article
- Review
- Mushroom Polysaccharides as Potential Candidates for Alleviating Neurodegenerative Diseases.Nutrients · 2022Review
- Protective Effects of Polysaccharides in Neurodegenerative Diseases.Frontiers in aging neuroscience · 2022Review
- Natural Polysaccharides as Preventive and Therapeutic Horizon for Neurodegenerative Diseases.Pharmaceutics · 2021Review
- Anti-Inflammatory and Immunomodulatory Effects of thePharmaceutics · 2021Article
- Sulfated Polysaccharide Isolated from the Nacre of Pearl Oyster Improves Scopolamine-Induced Memory Impairment.Antioxidants (Basel, Switzerland) · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Alzheimer's disease (AD) is characterized by the deposition of amyloid-β (Aβ) plaques, neuronal loss and neurofibrillary tangles. In addition, neuroinflammatory processes are thought to contribute to AD pathophysiology. Maitake (
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.